Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carisbamate for painful diabetic peripheral neuropathy
NL-OMON33350Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of carisbamate in diabetic polyneuropathy (DPN) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Average daily pain and Safety and tolerability. Started Jun 2009; status: active, not recruiting.
02
Drugs
carisbamate
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NL-OMON33350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33350.